iCo ophthalmic, autoimmune, infectious news

iCo terminated all employees to preserve cash. In 2014, iCo reported that iCo-007 failed in a Phase II trial to treat diabetic macular edema (DME). The company said it has

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE